Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MedImmune chronicles

MedImmune chronicles

Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior to last week's acquisition announcement, MEDI was off 13% from the start of 2000, while an index of its peers was up 116%. Below are selected MEDI events tracked against the company's weekly stock

Read the full 682 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE